J. Bruix, M. Reig, and M. Sherman, Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma, Gastroenterology, vol.150, pp.835-853, 2016.

, European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma, J. Hepatol, vol.56, pp.908-943, 2012.

J. Bruix and M. Sherman, Management of hepatocellular carcinoma: An update, Hepatology, vol.53, pp.1020-1022, 2011.

K. Kee, J. Wang, and C. Lin, Validation of the 7th edition TNM staging system for hepatocellular carcinoma: an analysis of 8,828 patients in a single medical center, Dig. Dis. Sci, vol.58, pp.2721-2728, 2013.

K. Okuda, T. Ohtsuki, and H. Obata, Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients, Cancer, vol.56, pp.918-928, 1985.

. Anon, A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators, Hepatol. Baltim. Md, vol.28, pp.751-755, 1998.

J. M. Llovet, C. Brú, and J. Bruix, Prognosis of hepatocellular carcinoma: the BCLC staging classification, Semin. Liver Dis, vol.19, pp.329-338, 1999.

H. B. El-serag, Hepatocellular carcinoma, N. Engl. J. Med, vol.365, pp.1118-1127, 2011.

F. Borie, B. Trétarre, and A. Bouvier, Primitive liver cancers: epidemiology and geographical study in France, Eur. J. Gastroenterol. Hepatol, vol.21, pp.984-989, 2009.

J. Ferlay, I. Soerjomataram, and R. Dikshit, Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, Int. J. Cancer, vol.136, pp.359-386, 2015.

S. Mittal and H. B. El-serag, Epidemiology of hepatocellular carcinoma: consider the population, J. Clin. Gastroenterol, vol.47, pp.2-6, 2013.

C. Bosetti, F. Turati, L. Vecchia, and C. , Hepatocellular carcinoma epidemiology. Best Pract. Res. Clin. Gastroenterol, vol.28, pp.753-770, 2014.

C. Bosetti, F. Levi, and P. Boffetta, Trends in mortality from hepatocellular carcinoma in Europe, Hepatol. Baltim. Md, vol.48, pp.137-145, 1980.

. Anon, Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2012. Étude à partir des registres des cancers du réseau français. Partie 1-Tumeurs solides, juillet 2013, 2013.

B. Njei, Y. Rotman, and I. Ditah, Emerging trends in hepatocellular carcinoma incidence and mortality, Hepatol. Baltim. Md, vol.61, pp.191-199, 2015.

A. Sangiovanni, G. M. Prati, and P. Fasani, The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients, Hepatol. Baltim. Md, vol.43, pp.1303-1310, 2006.

G. Fattovich, T. Stroffolini, and I. Zagni, Hepatocellular carcinoma in cirrhosis: incidence and risk factors, Gastroenterology, vol.127, pp.35-50, 2004.

S. Lee, B. K. Kim, and S. U. Kim, Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study, J. Gastroenterol. Hepatol, vol.29, pp.1463-1469, 2014.

K. Joshi, A. Kohli, and R. Manch, Alcoholic Liver Disease: High Risk or Low Risk for Developing Hepatocellular Carcinoma? Clin, Liver Dis, vol.20, pp.563-580, 2016.

A. Mancebo, M. L. González-diéguez, and V. Cadahía, Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups, Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc, vol.11, pp.95-101, 2013.

S. Locarnini, A. Hatzakis, and D. Chen, Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs, J. Hepatol, vol.62, pp.76-86, 2015.

J. J. Ott, G. A. Stevens, and J. Groeger, Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity, Vaccine, vol.30, pp.2212-2219, 2012.

Y. Tan, Hepatitis B virus infection and the risk of hepatocellular carcinoma, World J. Gastroenterol, vol.17, pp.4853-4857, 2011.

M. Levrero and J. Zucman-rossi, Mechanisms of HBV-induced hepatocellular carcinoma, J. Hepatol, vol.64, pp.84-101, 2016.

J. D. Yang, W. R. Kim, and R. Coelho, Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma, Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc, vol.9, pp.64-70, 2011.

F. Liu, X. Wang, and L. Chen, Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance, Aliment. Pharmacol. Ther, vol.43, pp.1253-1261, 2016.

S. M. Lemon and D. R. Mcgivern, Is hepatitis C virus carcinogenic?, Gastroenterology, vol.142, pp.1274-1278, 2012.

R. H. Westbrook and G. Dusheiko, Natural history of hepatitis C, J. Hepatol, vol.61, pp.58-68, 2014.

A. G. Singal and H. B. El-serag, Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice, Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc, vol.13, pp.2140-2151, 2015.

C. Bertot, L. Adams, and L. A. , The Natural Course of Non-Alcoholic Fatty Liver Disease, Int. J. Mol. Sci, vol.17, 2016.

I. C. Hsu, R. A. Metcalf, and T. Sun, Mutational hotspot in the p53 gene in human hepatocellular carcinomas, Nature, vol.350, pp.427-428, 1991.

G. Goh, P. Chang, and C. Tan, Changing epidemiology of hepatocellular carcinoma in Asia, Best Pract. Res. Clin. Gastroenterol, vol.29, pp.919-928, 2015.

Y. Yang, Q. Wu, and L. Xie, Prospective cohort studies of association between family history of liver cancer and risk of liver cancer, Int. J. Cancer, vol.135, pp.1605-1614, 2014.

G. Cabibbo, M. Maida, and C. Genco, Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study, World J. Hepatol, vol.4, pp.256-261, 2012.

E. G. Giannini, F. Farinati, and F. Ciccarese, Prognosis of untreated hepatocellular carcinoma, Hepatol. Baltim. Md, vol.61, pp.184-190, 2015.

G. Cao, X. Li, and C. Qin, Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis, Med. Sci. Monit. Int. Med. J. Exp. Clin. Res, vol.21, pp.3144-3151, 2015.

K. Tsuchiya, Y. Asahina, and S. Matsuda, Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma, Cancer, vol.120, pp.229-237, 2014.

M. Scartozzi, L. Faloppi, S. Baroni, and G. , VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study, Int. J. Cancer, vol.135, pp.1247-1256, 2014.

J. M. Llovet, S. Ricci, and V. Mazzaferro, Sorafenib in advanced hepatocellular carcinoma, N. Engl. J. Med, vol.359, pp.378-390, 2008.

A. Cheng, Y. Kang, and Z. Chen, Efficacy and safety of sorafenib in patients in the AsiaPacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, Lancet Oncol, vol.10, pp.25-34, 2009.

R. Lencioni, M. Kudo, and S. Ye, Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis, Int. J. Clin. Pract, vol.68, pp.609-617, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01689426

J. A. Marrero, M. Kudo, and A. P. Venook, Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study, J. Hepatol, 2016.

R. Dienstmann, I. Braña, and J. Rodon, Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs, The Oncologist, vol.16, pp.1729-1740, 2011.

M. Reig, F. Torres, and C. Rodriguez-lope, Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib, J. Hepatol, vol.61, pp.318-324, 2014.

J. Cho, Y. Paik, and H. Y. Lim, Clinical parameters predictive of outcomes in sorafenibtreated patients with advanced hepatocellular carcinoma, Liver Int. Off. J. Int. Assoc. Study Liver, vol.33, pp.950-957, 2013.

A. L. Inghilesi, D. Gallori, and L. Antonuzzo, Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib, World J. Gastroenterol, vol.20, pp.786-794, 2014.

S. Colagrande, F. Regini, and G. G. Taliani, Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up, World J. Hepatol, vol.7, pp.1041-1053, 2015.

Y. Shao, W. Shau, and S. Chan, Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: a meta-analysis of randomized clinical trials, Oncology, vol.88, pp.345-352, 2015.

Y. Shao, C. Hsu, and A. Cheng, Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?, World J. Gastroenterol. WJG, vol.21, pp.10336-10347, 2015.

S. Ogasawara, T. Chiba, and Y. Ooka, Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors, Invest. New Drugs, vol.33, pp.729-739, 2015.

S. Ogasawara, T. Chiba, and Y. Ooka, Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma, PloS One, vol.11, p.161303, 2016.

F. Petrelli, M. Cabiddu, and A. Coinu, Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies, Acta Oncol. Stockh. Swed, vol.54, pp.961-970, 2015.

R. Sacco, V. Mismas, and A. Romano, Assessment of clinical and radiological response to sorafenib in hepatocellular carcinoma patients, World J. Hepatol, vol.7, pp.33-39, 2015.

M. Chen, T. Therneau, and L. S. Orsini, Design and rationale of the HCC BRIDGE study in China: a longitudinal, multicenter cohort trial in hepatocellular carcinoma, BMC Gastroenterol, vol.11, p.53, 2011.

X. Gong and S. Qin, Progress in systemic therapy of advanced hepatocellular carcinoma, World J. Gastroenterol, vol.22, pp.6582-6594, 2016.

M. P. Brizzi, D. Pignataro, and M. Tampellini, Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?, Expert Rev. Anticancer Ther, 2016.

K. Mross, A. Frost, and S. Steinbild, A phase I dose-escalation study of regorafenib (BAY 734506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.18, pp.2658-2667, 2012.

J. Bruix, W. Tak, and A. Gasbarrini, Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study, Eur. J. Cancer Oxf. Engl, vol.49, pp.3412-3419, 1990.

A. B. El-khoueiry, I. Malero, and T. C. , Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): Ca209-040, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol

B. Sangro, C. Gomez-martin, and . Mata-m-de-la, A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C, J. Hepatol, vol.59, pp.81-88, 2013.

V. Hernandez-gea, S. Toffanin, and S. L. Friedman, Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma, Gastroenterology, vol.144, pp.512-527, 2013.

C. Brenner, L. Galluzzi, and O. Kepp, Decoding cell death signals in liver inflammation, J. Hepatol, vol.59, pp.583-594, 2013.

C. I. Diakos, K. A. Charles, and D. C. Mcmillan, Cancer-related inflammation and treatment effectiveness, Lancet Oncol, vol.15, pp.493-503, 2014.

R. D. Schreiber, L. J. Old, and M. J. Smyth, Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, Science, vol.331, pp.1565-1570, 2011.

M. D. Vesely and R. D. Schreiber, Cancer Immunoediting: antigens, mechanisms and implications to cancer immunotherapy, Ann. N. Y. Acad. Sci, vol.1284, pp.1-5, 2013.

A. I. Jacob, P. K. Goldberg, and N. Bloom, Endotoxin and bacteria in portal blood, Gastroenterology, vol.72, pp.1268-1270, 1977.

M. Tagliamonte, A. Petrizzo, and M. L. Tornesello, Combinatorial immunotherapy strategies for hepatocellular carcinoma, Curr. Opin. Immunol, vol.39, pp.103-113, 2016.

D. Kuang, Q. Zhao, and Y. Wu, Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma, J. Hepatol, vol.54, pp.948-955, 2011.

X. Zhu, J. Zhang, and P. Zhuang, High Expression of Macrophage Colony-Stimulating Factor in Peritumoral Liver Tissue Is Associated With Poor Survival After Curative Resection of Hepatocellular Carcinoma, J. Clin. Oncol, vol.26, pp.2707-2716, 2008.

T. Motomura, K. Shirabe, and Y. Mano, Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment, J. Hepatol, vol.58, pp.58-64, 2013.

W. H. Fridman and C. Sautès-fridman, Le microenvironnement tumoral: Matrice nourricière, champ de bataille et cible thérapeutique des cancers, médecine/sciences, vol.30, pp.359-365, 2014.

M. L. Disis, Immune Regulation of Cancer, J. Clin. Oncol, vol.28, pp.4531-4538, 2010.

J. Fu, D. Xu, and Z. Liu, Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients, Gastroenterology, vol.132, pp.2328-2339, 2007.

E. Unitt, A. Marshall, and W. Gelson, Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation, J. Hepatol, vol.45, pp.246-253, 2006.

C. Borg, I. Ray-coquard, and I. Philip, CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer, Cancer, vol.101, pp.2675-2680, 2004.

I. Ray-coquard, C. Cropet, and M. Van-glabbeke, Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas, Cancer Res, vol.69, pp.5383-5391, 2009.

W. H. Fridman, J. Galon, and F. Pagès, Prognostic and predictive impact of intra-and peritumoral immune infiltrates, Cancer Res, vol.71, pp.5601-5605, 2011.

A. T. Franco, A. Corken, and J. Ware, Platelets at the interface of thrombosis, inflammation, and cancer, Blood, vol.126, pp.582-588, 2015.

M. Labelle, S. Begum, and R. O. Hynes, Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis, Cancer Cell, vol.20, pp.576-590, 2011.

N. Li, Platelets in cancer metastasis: To help the "villain" to do evil, Int. J. Cancer, vol.138, pp.2078-2087, 2016.

C. Bihari, A. Rastogi, and S. M. Shasthry, Platelets contribute to growth and metastasis in hepatocellular carcinoma, APMIS Acta Pathol. Microbiol. Immunol. Scand, vol.124, pp.776-786, 2016.
DOI : 10.1111/apm.12574

G. H. Choi, S. Han, and J. H. Shim, Prognostic Scoring Models for Patients Undergoing Sorafenib Treatment for Advanced Stage Hepatocellular Carcinoma in Real-Life Practice, Am. J. Clin. Oncol, 2014.
DOI : 10.1097/coc.0000000000000132

S. Ishigami, S. Natsugoe, and K. Tokuda, Tumor-associated macrophage (TAM) infiltration in gastric cancer, Anticancer Res, vol.23, pp.4079-4083, 2003.

R. Liao, N. Jiang, and Z. Tang, Systemic and intratumoral balances between monocytes/macrophages and lymphocytes predict prognosis in hepatocellular carcinoma patients after surgery, Oncotarget, vol.7, pp.30951-30961, 2016.
DOI : 10.18632/oncotarget.9049

URL : http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=9049&path%5B%5D=27421

M. R. Galdiero, E. Bonavita, and I. Barajon, Tumor associated macrophages and neutrophils in cancer, Immunobiology, vol.218, pp.1402-1410, 2013.
DOI : 10.1016/j.imbio.2013.06.003

D. Capece, M. Fischietti, and D. Verzella, The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages, BioMed Res. Int, p.187204, 2013.

Q. Lahmar, J. Keirsse, and D. Laoui, Tissue-resident versus monocyte-derived macrophages in the tumor microenvironment, Biochim. Biophys. Acta, vol.1865, pp.23-34, 2016.

T. F. Nishijima, H. B. Muss, and S. S. Shachar, Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: A systematic review and meta-analysis, Cancer Treat. Rev, vol.41, pp.971-978, 2015.

W. Xiao, C. D. Li, and S. , Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis, BMC Cancer, vol.14, p.117, 2014.

Y. Zheng, W. Zhao, and B. Liu, The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib. Asian Pac, J. Cancer Prev. APJCP, vol.14, pp.5527-5531, 2013.

. Fonseca-lg-da, R. Barroso-sousa, . Bento-a-da, and . Sa, Pre-treatment neutrophil-tolymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib, Med. Oncol. Northwood Lond. Engl, vol.31, p.264, 2014.

Q. Lai, C. Santa, E. , R. Juri, and J. M. , Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer, Transpl. Int. Off. J. Eur. Soc. Organ Transplant, vol.27, pp.32-41, 2014.

X. Li, Z. Chen, and Y. Xing, Platelet-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma, Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med, vol.36, pp.2263-2269, 2015.
DOI : 10.1007/s13277-014-2833-9

C. Li, T. Wen, and L. Yan, Postoperative neutrophil-to-lymphocyte ratio plus platelet-tolymphocyte ratio predicts the outcomes of hepatocellular carcinoma, J. Surg. Res, vol.198, pp.73-79, 2015.

Q. Pang, J. Zhang, and X. Xu, Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence, World J. Gastroenterol, vol.21, pp.5607-5621, 2015.
DOI : 10.3748/wjg.v21.i18.5607

URL : http://europepmc.org/articles/pmc4427685?pdf=render

A. J. Templeton, M. G. Mcnamara, and B. ?eruga, Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis, J. Natl. Cancer Inst, vol.106, p.124, 2014.

Z. Lin, D. Ruan, and Y. Li, Lymphocyte-to-monocyte ratio predicts survival of patients with hepatocellular carcinoma after curative resection, World J. Gastroenterol, vol.21, pp.10898-10906, 2015.

S. Wu, Y. Lin, and H. Ye, Lymphocyte to monocyte ratio and prognostic nutritional index predict survival outcomes of hepatitis B virus-associated hepatocellular carcinoma patients after curative hepatectomy, J. Surg. Oncol, vol.114, pp.202-210, 2016.
DOI : 10.1002/jso.24297

B. Hu, X. Yang, and Y. Xu, Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.20, pp.6212-6222, 2014.
DOI : 10.1158/1078-0432.ccr-14-0442

URL : http://clincancerres.aacrjournals.org/content/20/23/6212.full.pdf

Z. Yang, J. Zhang, and Y. Lu, Aspartate aminotransferase-lymphocyte ratio index and systemic immune-inflammation index predict overall survival in HBV-related hepatocellular carcinoma patients after transcatheter arterial chemoembolization, Oncotarget, vol.6, pp.43090-43098, 2015.
DOI : 10.18632/oncotarget.5719

URL : http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=5719&path%5B%5D=15621

A. Chan, S. L. Chan, and G. Wong, Prognostic Nutritional Index (PNI) Predicts Tumor Recurrence of Very Early/Early Stage Hepatocellular Carcinoma After Surgical Resection, Ann. Surg. Oncol, vol.22, pp.4138-4148, 2015.

W. Peng, C. Li, and T. Wen, Postoperative prognostic nutritional index change is an independent predictor of survival in patients with small hepatocellular carcinoma, Am. J. Surg, vol.212, pp.122-127, 2016.

Z. Zheng, L. Zhou, and S. Gao, Prognostic role of C-reactive protein in hepatocellular carcinoma: a systematic review and meta-analysis, Int. J. Med. Sci, vol.10, pp.653-664, 2013.

A. Kinoshita, H. Onoda, and N. Imai, The C-Reactive Protein/Albumin Ratio, a Novel Inflammation-Based Prognostic Score, Predicts Outcomes in Patients with Hepatocellular Carcinoma, Ann. Surg. Oncol, vol.22, pp.803-810, 2014.

T. Abe, H. Tashiro, and M. Hattori, Prediction of long-term survival by using the Glasgow Prognostic Score in patients with hepatocellular carcinoma after liver transplantation, Hepatol. Res, vol.46, pp.622-633, 2016.

M. Li, X. Bi, and Z. Li, Prognostic Role of Glasgow Prognostic Score in Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis, Medicine (Baltimore), vol.94, p.2133, 2015.

X. Ni, Y. Yi, and Y. Fu, Prognostic Value of the Modified Glasgow Prognostic Score in Patients Undergoing Radical Surgery for Hepatocellular Carcinoma, Medicine (Baltimore), vol.94, p.1486, 2015.

D. C. Mcmillan, The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer, Cancer Treat. Rev, vol.39, pp.534-540, 2013.

M. J. Proctor, D. S. Morrison, and D. Talwar, A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study, Eur. J. Cancer Oxf. Engl, vol.47, pp.2633-2641, 1990.

Y. Fu, X. Ni, and Y. Yi, A Novel and Validated Inflammation-Based Score (IBS) Predicts Survival in Patients With Hepatocellular Carcinoma Following Curative Surgical Resection: A STROBE-Compliant Article, Medicine (Baltimore), vol.95, p.2784, 2016.

P. Nagarajan, M. Kumar, M. J. Venkatesan, and R. , Genetically modified mouse models for the study of nonalcoholic fatty liver disease, World J. Gastroenterol. WJG, vol.18, pp.1141-1153, 2012.

S. Rekik, E. Guyot, and M. Bhais, The CRP level and STATE score predict survival in cirrhotic patients with hepatocellular carcinoma treated by transarterial embolization. Dig. Liver Dis, 2016.

J. Park, M. Chen, and M. Colombo, Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study, Liver Int, vol.35, pp.2155-2166, 2015.

J. M. Llovet, C. Peña, and C. D. Lathia, Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma, Clin. Cancer Res, vol.18, pp.2290-2300, 2012.

D. C. Mcmillan, Systemic inflammation, nutritional status and survival in patients with cancer, Curr. Opin. Clin. Nutr. Metab. Care, vol.12, pp.223-226, 2009.

M. J. Proctor, D. S. Morrison, and D. Talwar, A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study, Eur. J. Cancer Oxf. Engl, vol.47, pp.2633-2641, 1990.

S. Shrotriya, D. Walsh, and N. Bennani-baiti, C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review, PloS One, vol.10, p.143080, 2015.

A. J. Templeton, M. G. Mcnamara, and B. ?eruga, Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis, J. Natl. Cancer Inst, vol.106, p.124, 2014.

A. J. Templeton, O. Ace, and M. G. Mcnamara, Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis, Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol, vol.23, pp.1204-1212, 2014.

C. Roxburgh and D. C. Mcmillan, Role of systemic inflammatory response in predicting survival in patients with primary operable cancer, Future Oncol. Lond. Engl, vol.6, pp.149-163, 2010.

D. Bugada, M. Allegri, and P. Lavand'homme, Inflammation-based scores: a new method for patient-targeted strategies and improved perioperative outcome in cancer patients, BioMed Res. Int, p.142425, 2014.

Y. Liu, Z. Wang, and Y. Cao, Preoperative inflammation-based markers predict early and late recurrence of hepatocellular carcinoma after curative hepatectomy, Hepatobiliary Pancreat. Dis. Int. HBPD INT, vol.15, pp.266-274, 2016.

X. Li, Z. Chen, and Y. Xing, Platelet-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma, Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med, vol.36, pp.2263-2269, 2015.

X. Qi, J. Li, and H. Deng, Neutrophil-to-lymphocyte ratio for the prognostic assessment of hepatocellular carcinoma: A systematic review and meta-analysis of observational studies, Oncotarget, 2016.

K. Yamamura, H. Sugimoto, and M. Kanda, Comparison of inflammation-based prognostic scores as predictors of tumor recurrence in patients with hepatocellular carcinoma after curative resection, J. Hepato-Biliary-Pancreat. Sci, vol.21, pp.682-688, 2014.

T. M. Therneau, Extending the Cox model, 1996.

W. , The use of resampling methods to simplify regression models in medical statistics, Appl. Stat, 1999.

C. Lolli, U. Basso, and L. Derosa, Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib, Oncotarget, 2016.

A. Passardi, E. Scarpi, and L. Cavanna, Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer, Oncotarget, 2016.

A. Mantovani, P. Allavena, and A. Sica, Cancer-related inflammation, Nature, vol.454, pp.436-444, 2008.

D. Hanahan and R. A. Weinberg, Hallmarks of cancer: the next generation, Cell, vol.144, pp.646-674, 2011.

M. Labelle, S. Begum, and R. O. Hynes, Platelets guide the formation of early metastatic niches, Proc. Natl. Acad. Sci. U. S. A, vol.111, pp.3053-3061, 2014.

D. Schumacher, B. Strilic, and K. K. Sivaraj, Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor, Cancer Cell, vol.24, pp.130-137, 2013.

T. Xue, N. Ge, and X. Xu, High platelet counts increase metastatic risk in huge hepatocellular carcinoma undergoing transarterial chemoembolization, Hepatol. Res. Off. J. Jpn. Soc. Hepatol, 2016.

A. Hollebecque, S. Cattan, and O. Romano, Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score, Aliment. Pharmacol. Ther, vol.34, pp.1193-1201, 2011.

A. Hiraoka, M. Hirooka, and Y. Koizumi, Muscle volume loss as a prognostic marker in hepatocellular carcinoma patients treated with sorafenib, Hepatol. Res. Off. J. Jpn. Soc. Hepatol, 2016.

O. Huillard, O. Mir, and M. Peyromaure, Sarcopenia and body mass index predict sunitinibinduced early dose-limiting toxicities in renal cancer patients, Br. J. Cancer, vol.108, pp.1034-1041, 2013.

O. Mir, R. Coriat, and B. Blanchet, Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma, PloS One, vol.7, p.37563, 2012.

X. Ni, Y. Yi, and Y. Fu, Prognostic Value of the Modified Glasgow Prognostic Score in Patients Undergoing Radical Surgery for Hepatocellular Carcinoma, Medicine (Baltimore), vol.94, 2015.

K. Miyahara, K. Nouso, and T. Tomoda, Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma, J. Gastroenterol. Hepatol, vol.26, pp.1604-1611, 2011.